371 related articles for article (PubMed ID: 2736513)
1. Augmentation of antitumor efficacy by the combination of recombinant tumor necrosis factor and chemotherapeutic agents in vivo.
Krosnick JA; Mulé JJ; McIntosh JK; Rosenberg SA
Cancer Res; 1989 Jul; 49(14):3729-33. PubMed ID: 2736513
[TBL] [Abstract][Full Text] [Related]
2. Studies of effects of recombinant human tumor necrosis factor on autochthonous tumor and transplanted normal tissue in mice.
McIntosh JK; Mulé JJ; Travis WD; Rosenberg SA
Cancer Res; 1990 Apr; 50(8):2463-9. PubMed ID: 2317830
[TBL] [Abstract][Full Text] [Related]
3. Combination cytokine immunotherapy with tumor necrosis factor alpha, interleukin 2, and alpha-interferon and its synergistic antitumor effects in mice.
McIntosh JK; Mulé JJ; Krosnick JA; Rosenberg SA
Cancer Res; 1989 Mar; 49(6):1408-14. PubMed ID: 2784349
[TBL] [Abstract][Full Text] [Related]
4. Synergistic antitumor effects of immunotherapy with recombinant interleukin-2 and recombinant tumor necrosis factor-alpha.
McIntosh JK; Mulé JJ; Merino MJ; Rosenberg SA
Cancer Res; 1988 Jul; 48(14):4011-7. PubMed ID: 3260130
[TBL] [Abstract][Full Text] [Related]
5. Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo.
Asher A; Mulé JJ; Reichert CM; Shiloni E; Rosenberg SA
J Immunol; 1987 Feb; 138(3):963-74. PubMed ID: 3805720
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of recombinant human tumor necrosis factor in combination with hyperthermia, chemotherapy, or immunotherapy.
Haranaka K; Sakurai A; Satomi N
J Biol Response Mod; 1987 Aug; 6(4):379-91. PubMed ID: 3625230
[TBL] [Abstract][Full Text] [Related]
7. Successful immunotherapy of mouse melanoma and sarcoma with recombinant interleukin-2 and cyclophosphamide.
Silagi S; Schaefer AE
J Biol Response Mod; 1986 Oct; 5(5):411-22. PubMed ID: 3490544
[TBL] [Abstract][Full Text] [Related]
8. In vivo induction of IL-6 by administration of exogenous cytokines and detection of de novo serum levels of IL-6 in tumor-bearing mice.
McIntosh JK; Jablons DM; Mulé JJ; Nordan RP; Rudikoff S; Lotze MT; Rosenberg SA
J Immunol; 1989 Jul; 143(1):162-7. PubMed ID: 2499626
[TBL] [Abstract][Full Text] [Related]
9. Combined effects of chemotherapy and interleukin 2 in the therapy of mice with advanced pulmonary tumors.
Papa MZ; Yang JC; Vetto JT; Shiloni E; Eisenthal A; Rosenberg SA
Cancer Res; 1988 Jan; 48(1):122-9. PubMed ID: 3257159
[TBL] [Abstract][Full Text] [Related]
10. Antileukemic effects of recombinant human tumor necrosis factor alpha (rh-TNF alpha) with cyclophosphamide or methotrexate on leukemia L1210 and leukemia P388 in mice.
Warzocha K; Robak T
Acta Haematol Pol; 1992; 23(1):55-62. PubMed ID: 1615753
[TBL] [Abstract][Full Text] [Related]
11. Effects of TNF alone or in combination with chemotherapeutic agents on human ovarian cancers in vitro and in nude mice.
Zhao E; Zhou M; Fu C; Shen B; Zhang Q; Lian L
Chin Med J (Engl); 1995 Aug; 108(8):571-5. PubMed ID: 7587485
[TBL] [Abstract][Full Text] [Related]
12. Modulation of 5-fluorouracil host-toxicity and chemotherapeutic efficacy against human colon tumors by 5-(Phenylthio)acyclouridine, a uridine phosphorylase inhibitor.
Al Safarjalani ON; Rais R; Shi J; Schinazi RF; Naguib FN; el Kouni MH
Cancer Chemother Pharmacol; 2006 Nov; 58(5):692-8. PubMed ID: 16528530
[TBL] [Abstract][Full Text] [Related]
13. Manipulation of oxygen radical-scavenging capacity in mice alters host sensitivity to tumor necrosis factor toxicity but does not interfere with its antitumor efficacy.
Hauser GJ; McIntosh JK; Travis WD; Rosenberg SA
Cancer Res; 1990 Jun; 50(12):3503-8. PubMed ID: 2340500
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms by which chemotherapeutic agents augment the antitumor effects of tumor necrosis factor: involvement of the pattern shift of cytokines from Th2 to Th1 in tumor lesions.
Inagawa H; Nishizawa T; Honda T; Nakamoto T; Takagi K; Soma G
Anticancer Res; 1998; 18(5D):3957-64. PubMed ID: 9854510
[TBL] [Abstract][Full Text] [Related]
15. Schedule-dependent variations in the response of murine P388 leukemia to cyclophosphamide in combination with interferons-alpha/beta.
Borden EC; Sidky YA; Hatcher JF; Bryan GT
Cancer Res; 1988 May; 48(9):2329-34. PubMed ID: 3356000
[TBL] [Abstract][Full Text] [Related]
16. The influence of recombinant human tumor necrosis factor-alpha, alone and in combination with cyclophosphamide or methotrexate, on leukemia L1210 and normal hematopoiesis in mice.
Warzocha K; Robak T; Korycka A; Graczyk J; Pakulska W; Gałazka G; Kłysik J
Arch Immunol Ther Exp (Warsz); 1991; 39(5-6):587-95. PubMed ID: 1841555
[TBL] [Abstract][Full Text] [Related]
17. Chemoprotective effects of recombinant human IL-1 alpha in cyclophosphamide-treated normal and tumor-bearing mice. Protection from acute toxicity, hematologic effects, development of late mortality, and enhanced therapeutic efficacy.
Futami H; Jansen R; MacPhee MJ; Keller J; McCormick K; Longo DL; Oppenheim JJ; Ruscetti FW; Wiltrout RH
J Immunol; 1990 Dec; 145(12):4121-30. PubMed ID: 2258610
[TBL] [Abstract][Full Text] [Related]
18. [Combined effect of TNF and anticancer chemotherapeutic agents on murine bladder tumor (MBT-2)].
Ikemoto S; Iimori H; Nishimoto K; Hayahara N; Kamizuru M; Wada S; Hayahara M
Hinyokika Kiyo; 1992 Mar; 38(3):285-9. PubMed ID: 1523983
[TBL] [Abstract][Full Text] [Related]
19. Augmentation of antitumor effect of endogenously induced tumor necrosis factor by cyclophosphamide.
Inagawa H; Ohshiro S; Nishizawa T; Goto S; Soma G; Mizuno D
Anticancer Res; 1997; 17(1A):55-60. PubMed ID: 9066630
[TBL] [Abstract][Full Text] [Related]
20. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
Papa MZ; Mulé JJ; Rosenberg SA
Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
